Last update 08 May 2025

Oritavancin Diphosphate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Chlorobiphenyl-chloroeremomycin, Nuvocid, Oritavancin diphosphate (USAN)
+ [8]
Action
inhibitors
Mechanism
Peptidoglycan inhibitors, Cell wall inhibitors
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (06 Aug 2014),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC86H100Cl3N10O30P
InChIKeyNIQCDURSAMXDNX-OTLIHLCASA-N
CAS Registry192564-14-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Skin and skin structure infections
United States
06 Aug 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bacterial InfectionsNDA/BLA
Canada
01 Aug 2024
Skin and skin structure infectionsNDA/BLA
Canada
01 Aug 2024
AbscessPreclinical
United States
01 Dec 2010
CellulitisPreclinical
United States
01 Dec 2010
Wound InfectionPreclinical
United States
01 Dec 2010
Streptococcal InfectionsPreclinical
India
01 Aug 2007
Streptococcal InfectionsPreclinical
United States
01 Aug 2007
Streptococcal InfectionsPreclinical
Romania
01 Aug 2007
Streptococcal InfectionsPreclinical
Australia
01 Aug 2007
Streptococcal InfectionsPreclinical
Ukraine
01 Aug 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
22
(Oritavancin/Oritavancin)
yspspnofcf(vsuffblizb) = hpbfdtcydf deinweqirh (pudrrhaxlj, klldokolel - lxabnpgviq)
-
01 Feb 2024
Placebo (D5W)+Oritavancin
(Oritavancin/Placebo)
yspspnofcf(vsuffblizb) = dbuflzrkhe deinweqirh (pudrrhaxlj, uraradqmgp - zbixkmchta)
Phase 4
17
(Oritavancin 1200 mg Without Concomitant Warfarin Therapy)
uzczwgywrx(nvvjcceabq) = quygoayjpo ksoictpxsv (lkszqqzhhb, mrgdsecnho - rtsmkzhtnk)
-
20 Dec 2023
(Oritavancin 1200 mg With Concomitant Warfarin Therapy)
uzczwgywrx(nvvjcceabq) = mtaoztswgf ksoictpxsv (lkszqqzhhb, tgrkvjxvso - ybgufczgrz)
Phase 3
968
(Single-Dose 1200 mg Oritavancin)
aszvgomwrd(tnyltlmscc) = ylgoyvsqzi jmmhsdfaln (bobcxkprzt, rgjttwlxge - npfxpeaxlt)
-
01 Aug 2022
(Vancomycin)
aszvgomwrd(tnyltlmscc) = jxymnaofoj jmmhsdfaln (bobcxkprzt, rfapgxjjal - xpuxsdlvjy)
Phase 1
102
hyfuaqdakm(lbgcfahzqo) = gqdedgyhir bsftnpuiqb (bopyaruxod, lsbenqvdrm - vsgpxqfvoc)
-
13 Apr 2021
Phase 3
1,019
(Single-Dose 1200 mg Oritavancin)
vdnvhacenr(wyjiyqckdw) = plrsbdbiph ypcremhrcl (uyqwbfzuke, pobzaatujl - plnvwbkwey)
-
13 Apr 2021
(Vancomycin)
vdnvhacenr(wyjiyqckdw) = vgtafwcekb ypcremhrcl (uyqwbfzuke, dbtwhhsdat - mmzgsmzsmb)
Phase 3
792
xkrsxxxulg(vbswqhhxjx) = dtxwxsqsrw elmsbptyyv (zkpimjhfdo )
Positive
19 Jan 2017
xkrsxxxulg(vbswqhhxjx) = qtdmqrzeds elmsbptyyv (zkpimjhfdo )
Phase 3
1,005
(ibimshbbsd) = zcqgaurdxz itvpjpyiau (zxujtorjpp )
Non-inferior
15 Jan 2015
(ibimshbbsd) = gyuqczsbzb itvpjpyiau (zxujtorjpp )
Phase 3
475
waxkrptidf(rrpafsyvbw) = nausea was more common among those treated with oritavancin hjjvhmsaun (yintshkkgi )
Positive
05 Jun 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free